Peptides

PTD-DBM: molecular data, studies & sources

PTD-DBM is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked 2026-10-09 · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular record not yet resolved

A sufficiently specific molecular record was not resolved for this name. Formula, molecular weight and structure are withheld until the exact sequence, salt or preparation can be verified.

MF: not assigned · MW: not assigned · Structure: not assigned

Registered clinical trials

Studies registered on ClinicalTrials.gov that list PTD-DBM as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

No registered study naming this compound was matched. This is a documented gap in registry coverage, not proof that no study exists.

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received PTD-DBM, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

Preclinical / laboratory research
The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing.
Lee SH, Kim MY, Kim HY et al. · The Journal of experimental medicine · 2015
PMID 26056233 · DOI: 10.1084/jem.20141601
Preclinical / laboratory research
Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis.
Lee SH, Seo SH, Lee DH et al. · The Journal of investigative dermatology · 2017
PMID 28595998 · DOI: 10.1016/j.jid.2017.04.038
Preclinical / laboratory research
CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2.
Ryu YC, Park J, Kim YR et al. · Cells · 2023
PMID 36831222 · DOI: 10.3390/cells12040555

PTD-DBM supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.